Number of eligible individuals: CDEC reviewed the uncertainty in the volume of people with reasonably intense to severe hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific specialists consulted by CADTH indicated that some patients who are classified as getting mild or moderate illness may have a severe bleeding phenotype, whi